Literature DB >> 9476664

Tales of tails: regulation of telomere length and telomerase activity during lymphocyte development, differentiation, activation, and aging.

N P Weng1, L D Palmer, B L Levine, H C Lane, C H June, R J Hodes.   

Abstract

Telomerase activity and the regulation of telomere length are factors which have been implicated in the control of cellular replication. These variables have been examined during human lymphocyte development, differentiation, activation, and aging. It was found that telomere length of peripheral blood CD4+ T cells decreases with age as well as with differentiation from naive to memory cells in vivo, and decreases with cell division in vitro. These results provide evidence that telomere length correlates with lymphocyte replicative history and residual replicative potential. In contrast, telomere length appears to increase during tonsil B-cell differentiation and germinal center (GC) formation in vivo. It was also found that telomerase activity is highly regulated during T-cell development and B-cell differentiation in vivo, with high levels of telomerase activity expressed in thymocytes and GC B cells, and low levels of telomerase activity in resting mature peripheral blood lymphocytes. Finally, resting lymphocytes retain the ability to upregulate telomerase activity upon activation, and this capacity does not appear to decline with age. Although the precise role of telomerase in lymphocyte function remains to be elucidated, telomerase may contribute to protection from telomere shortening in T and B lymphocytes, and may thus play a critical role in lymphocyte development, differentiation and activation. The future study of telomerase and its regulation of telomere length may enhance our understanding of how the replicative lifespan is regulated in lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9476664     DOI: 10.1111/j.1600-065x.1997.tb01026.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  50 in total

Review 1.  How long should telomeres be?

Authors:  A Aviv; C B Harley
Journal:  Curr Hypertens Rep       Date:  2001-04       Impact factor: 5.369

Review 2.  The role of telomerase expression and telomere length maintenance in human and mouse.

Authors:  N P Weng; R J Hodes
Journal:  J Clin Immunol       Date:  2000-07       Impact factor: 8.317

Review 3.  The peripheral generation of CD4+ CD25+ regulatory T cells.

Authors:  Arne N Akbar; Leonie S Taams; Mike Salmon; Milica Vukmanovic-Stejic
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

4.  Immortalization of human and rhesus macaque primary antigen-specific T cells by retrovirally transduced telomerase reverse transcriptase.

Authors:  Eugene V Barsov
Journal:  Curr Protoc Immunol       Date:  2011-11

Review 5.  A challenge for the future: aging and HIV infection.

Authors:  Tammy M Rickabaugh; Beth D Jamieson
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

Review 6.  T cell engineering as therapy for cancer and HIV: our synthetic future.

Authors:  Carl H June; Bruce L Levine
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-10-19       Impact factor: 6.237

Review 7.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

8.  Engineering T cells for cancer: our synthetic future.

Authors:  Robert H Vonderheide; Carl H June
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Accelerated telomere shortening in response to life stress.

Authors:  Elissa S Epel; Elizabeth H Blackburn; Jue Lin; Firdaus S Dhabhar; Nancy E Adler; Jason D Morrow; Richard M Cawthon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-01       Impact factor: 11.205

Review 10.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.